Oncostatin M synergistically inhibits HCV RNA replication in combination with interferon-alpha

FEBS Lett. 2009 May 6;583(9):1434-8. doi: 10.1016/j.febslet.2009.03.054. Epub 2009 Mar 28.

Abstract

Oncostatin M (OSM), a member of the interleukin-6 family, possesses various functions, including hepatocyte differentiation and suppression of melanoma cell growth. Here, we report anti-hepatitis C virus (HCV) activity of OSM as a new function of this cytokine. OSM possessed marked anti-HCV activity (50% effective concentration: 0.71 ng/ml) in an HCV RNA replication cell culture system. The most striking finding is that OSM exhibited synergistic inhibitory activity on interferon (IFN)-alpha even at a low concentration with weak anti-HCV activity, such as 25 pg/ml. OSM is a candidate anti-HCV reagent and may improve the current IFN therapy for patients with chronic hepatitis C.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antiviral Agents / administration & dosage
  • Antiviral Agents / pharmacology*
  • Blotting, Western
  • Cell Line
  • Dose-Response Relationship, Drug
  • Drug Synergism
  • Hepacivirus / drug effects*
  • Hepacivirus / genetics
  • Interferon-alpha / administration & dosage
  • Interferon-alpha / pharmacology*
  • Oncostatin M / administration & dosage
  • Oncostatin M / pharmacology*
  • RNA, Viral / biosynthesis*
  • Reverse Transcriptase Polymerase Chain Reaction

Substances

  • Antiviral Agents
  • Interferon-alpha
  • RNA, Viral
  • Oncostatin M